Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine

The current study examined the safety and immunogenicity of 23-valent pneumococcal capsular polysaccharide vaccine (Pneumo23(®) [PPV23], Sanofi Pasteur) as a booster dose in 12- to 18-month-old children primed with heptavalent pneumococcal vaccine (PCV7; Prevnar(®), Pfizer). This was a randomized, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Thisyakorn, Usa, Chokephaibulkit, Kulkanya, Kosalaraksa, Pope, Benjaponpitak, Suwat, Pancharoen, Chitsanu, Chuenkitmongkol, Sunate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186054/
https://www.ncbi.nlm.nih.gov/pubmed/25424793
http://dx.doi.org/10.4161/hv.28642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186054/
https://www.ncbi.nlm.nih.gov/pubmed/25424793
http://dx.doi.org/10.4161/hv.28642

Ejemplares similares